Vaccine Adjuvants Market Size, Share, Trend Forecast 2021
According to research report the report the Vaccine
Adjuvants Market is expected
to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of
10.5% from 2016 to 2021. The report provides a detailed overview of the major
drivers, restraints, challenges, opportunities, current market trends, and
strategies impacting the vaccine adjuvants market along with the estimates and
forecasts of the revenue and market share
analysis.
The global vaccine adjuvants market The major factors
driving the growth of this market are high prevalence of infectious and
zoonotic diseases, increasing focus on immunization programs by various
government bodies, and growing focus on improved and long-lasting immunization
against existing and emerging diseases.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894
The report segments this market into product type, route
of administration, disease type, applications, and application categories. On
the basis of product type, the vaccine adjuvants market is segmented into
pathogen components, adjuvant emulsions, particulate adjuvants, combination
adjuvants, and others. Particulate adjuvants are expected to account for the
largest share of the market. Adjuvant emulsions, on the other hand, are
projected to grow at the highest CAGR from 2016 to 2021 due to factors such as
the proven efficacy and relatively fewer safety issues involved in the use of
adjuvant emulsions.
On the basis of route of administration, the vaccine
adjuvants market is segmented into oral, subcutaneous, intranasal,
intramuscular, intradermal, and others. The intramuscular segment is expected
to account for the largest share of the global vaccine adjuvants market in
2016. The rapidly growing geriatric population and increasing need for
development of better vaccines for improved immunization are the key factors
propelling the growth of this market.
On the basis of disease type, the vaccine adjuvants
market includes infectious diseases, cancer, and other diseases. The infectious
diseases segment is expected to account for the largest share of the global
vaccine adjuvants market in 2016. High incidences of diseases and research
investments in life sciences are the major factors driving the growth of this
market.
Based on applications, the global vaccine adjuvants
market is segmented into research and commercial applications. Research
applications are expected to account for the largest share of the market during
the forecast period. Growth in this segment is driven by factors such as
increasing need for better immunization for the increasing geriatric population
and increasing government funding in research to meet the unmet needs for safe
and effective vaccine adjuvants.
On the basis of application categories, the vaccine
adjuvants market is segmented into human and veterinary adjuvants. Adjuvants
for humans are expected to account for the largest share of the global vaccine
adjuvants market in 2016 and are expected to grow at a higher CAGR in the
application category segment.
The key players in the vaccine adjuvants market include
Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus,
Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.),
Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ
Biosciences (France).
Comments
Post a Comment